Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Atezolizumab/bevacizumab

Isolated adrenocorticotropic hormone deficiency, inflammatory arthritis and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ikeda Y, et al. Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series. Internal Medicine 62 : 3341-3346, No. 22, Jan 2023. Available from: URL: https://dx.doi.org/10.2169/internalmedicine.1446-22 Ikeda Y, et al. Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series. Internal Medicine 62 : 3341-3346, No. 22, Jan 2023. Available from: URL: https://dx.doi.org/10.2169/internalmedicine.1446-22
Metadaten
Titel
Atezolizumab/bevacizumab
Isolated adrenocorticotropic hormone deficiency, inflammatory arthritis and lack of efficacy
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52183-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Dexmedetomidine

Case report

Azacitidine